LCA-0321 / Lycia Therapeutics - LARVOL DELTA

LCA-0321 is a Novel Targeted Protein Degrader Designed to Specifically and Rapidly Eliminate TSHR Autoantibodies for the Treatment of Graves' Disease (ATA 2026) - No abstract available

Endocrine Disorders • Grave’s Disease

LCA-0321-01: Phase 1 Single Ascending and Multiple Ascending Dose Study with LCA-0321 (clinicaltrialsregister.eu) - P1 | N=48 | Not yet recruiting | Sponsor: Lycia Therapeutics Inc.

New P1 trial • Endocrine Disorders • Grave’s Disease

Lycia Therapeutics Announces the Appointment of Chin Lee, MD, MPH, as Chief Medical Officer and Reveals Immunology Pipeline (GlobeNewswire) - "The company is progressing its two lead programs towards the clinic, which target well-validated drivers of autoimmune and inflammatory diseases...LCA-0061 is a CataLYTAC degrader that catalytically degrades IgE, offering a potentially more effective treatment for IgE-mediated diseases, including food allergy, allergic asthma and chronic spontaneous urticaria. In preclinical studies, a single dose promoted rapid, deep and durable suppression of total and free IgE, outperforming omalizumab, an anti-IgE blocking antibody. The mechanism of LCA-0061 and early data indicate its potential to effectively treat a wide range of patients, regardless of IgE levels....LCA-0321 is a LYTAC degrader designed to specifically bind and rapidly deplete anti-TSHR autoantibodies, the underlying cause of Graves’ disease and its extrathyroidal manifestations, including thyroid eye disease. This approach has the potential to restore normal thyroid function without causing general immunosuppression."

New molecule • Preclinical • Asthma • Chronic Spontaneous Urticaria • Grave’s Disease • Immunology • Thyroid Eye Disease